文摘
The outcome and prognostic factors of allogeneic HSCT in adult patients with MDS harboring +8 were retrospectively analyzed. Age > 50 years, 2 or more additional cytogenetic abnormalities, and a high risk at the time of HSCT according to the FAB/WHO classification were significantly associated with a higher overall mortality. No significant impact on the outcome was observed in cases with 1 cytogenetic abnormality in addition to +8. Although more than half of the patients had advanced MDS at the time of HSCT, allogeneic HSCT offered a curative option for adult patients with MDS harboring +8.